The European Union (EU) Council Recommendation on rare diseases urged the member states to implement national and EU collaborative actions to improve the health care of rare disease patients. Following this recommendation, the European Commission launched a tender on newborn screening (NBS) to report on current practices of laboratory testing, form a network of experts and provide guidance on how to further implement NBS screening in a responsible way, the latter of which was provided in an Expert Opinion document. After consultation of experts from EU member states, (potential) candidate member states and European Free Trade Association countries, in a consensus meeting in June 2011, 70 expert opinions were finalized. They included the need to develop case definitions for all disorders screened for to facilitate assessment and international outcome studies. Decision whether a screening program should be performed can be based on screening criteria updated from the traditional Wilson and Jungner (1968) criteria, relating to disease, treatment, test and cost. The interest of the child should be central in the assessment of pros and cons. A European NBS body should assess evidence on (new) screening candidate disorders. For rare conditions, best level evidence should be used. The health system should ensure treatment to cases diagnosed by screening, controlled and revised by follow-up outcome studies. Screening methodology should aim to avoid unintended findings, such as mild forms and carrier status information, as much as possible. Activities to improve NBS in Europe, such as training and scientific evaluation, could benefit from collaboration at EU level and beyond.
The European Union (EU) Council Recommendation 1 on Rare Diseases (9 June 2009) 2 identified rare diseases (ie, a life-threatening or chronically debilitating condition affecting not more than five in 10 000 persons in the community) as a public health concern and highlighted the need for public health actions, promoting the development of research on rare disorders and the improvement of the health care of rare disease patients. Following this recommendation, the European Commission launched a tender on neonatal screening ( ¼ newborn screening, NBS) in July 2009 (http:// ec.europa.eu/eahc/health/tenders_H09C2.html) in order to (1) report on the practices of neonatal screening for rare disorders implemented in all the member states, including number of centers, estimate the number of infants screened and the number of disorders included in the NBS, as well as reasons for the selection of these disorders, (2) to identify types of medical management and follow-up implemented in the member states, (3) to establish a network of experts analyzing the information and formulating a final opinion containing recommendations on best practices, and recommending a core panel of NBS conditions that could be included in all MS practices, and (4) to develop a decision-making matrix that could be used by member states' programs to systematically expand (or contract) screening mandates.
The focus of the tender activities was on NBS by using laboratory testing techniques (blood spot screening). All reports are available on the internet (http://www.iss.it/cnmr/prog/cont.php?id=1621&lang=1&tipo=64).
To get some insight into the current practices (points 1 and 2 above), an online survey was compiled and filled out by EU member states, (potential) member states and European Free Trade Association countries -in total 40 countries. Apart from the final report, available on the internet, the current practices are summarized in two journal articles: the first publication addresses the steps in screening programmes from blood spot to screening result 3 and the second publication addresses the steps from screening laboratory results to treatment, follow-up and quality assurance. 4 As a third part of the activity and work methodology requested by the tender specifications, a European Union Network of Experts on Newborn Screening (EUNENBS) had to be constituted. Criteria for the inclusion of experts in EUNENBS (http://www.iss.it/cnmr/prog/ cont.php?id=1621&lang=1&tipo=64) include that all member states' authorities should be represented in the network. Each countries' competent authorities were invited to identify their experts to represent the country at the workshops in 2010 Experiences from other countries have served as useful sources, although their applicability may need to be checked against information from EU countries and agreement needs to be sought with EUNENBS. This article presents the 70 Expert Opinions, resulting from the debate among the EUNENBS members with respect to the elements that are part of a system to evaluate the quality and ethical aspects of neonatal screening in the light of available literature, as well as the proposal for a decision matrix. We furthermore provide a brief discussion.
RESULTS 1: EXPERT OPINIONS
Governance of neonatal screening 1. Screening is different from diagnostics. Screening is offered to people who either do not have or have not recognized the symptoms of the disease(s) that the screening relates to. A screening test is not intended to be diagnostic. Screening aims to identify people at sufficient risk to benefit from referral for diagnostics. 2. Haven taken notice of the fact that a European body for the HTA will be developed (European Network for Health Technology Assessment), 5, 6 the EUNENBS recommends a committee for neonatal screening. 3. This EU NBS committee should summarize the scientific developments (evidence, economics and ethics) 7 and advice transparently. It should update relevant information at national and European level. In addition, because it will gather the widest expertise on NBS at the EU level, it should act as a central point for any stakeholder (eg, learned societies, industry and patient groups) to propose and discuss new NBS procedures. 4. The EU NBS body should promote synergies and best practice guidelines on policies concerning consent, storage of samples, pretest information for parents, etc. (benchmarking, reviewing, updating and so on). 5. The body should have a clear governance structure and accountability. It should have a role in offering advice to (national) policy makers.
6. In each country, national bodies should assess the country-specific factors, including epidemiological, economical, ethical and legal issues, and perform the monitoring and evaluation of the program. 7. A formalised decision process is needed to start the HTA of a screening and to re-evaluate the evidence for screening either periodically or on demand. 8. Actors to be involved in NBS decision making include patients ' and parents' organizations, laboratory scientists, health-care workers and professional organizations, ethical, legal and economic experts, governmental and non-governmental agencies and health-care providers. 9. The role of industry, commercial parties or industrial researchers should be limited to consultation. 10. Existing examples of written policies should be translated and published, so that they could serve as examples for the countries that do not have such policies yet, but which are considering their development. The criteria used by national committees when considering new screening programs should be published. The examples of policies should cover both national and European practices in a way that could allow the assessment of trans-border issues (eg, equipment-related issues, access to relevant new technologies and appropriate screening for people moving from one country to another). 11. Systems should be in place within the EU to learn from potential generic adverse incidents that may cross national boundaries, for example, equipment-related issues. 12. Once the EU NBS body is in place and examples of good practices are available, it should be discussed to what extent harmonization of NBS in Europe is possible.
Criteria to evaluate whether a screening program should be performed
1. There is a clear need to develop and publish agreed case definitions for all disorders screened. There should be an attempt made to achieve agreement on these case definitions within the EU to facilitate assessment and international outcome studies. 2. The decision whether a screening program should be performed can be based on a framework of screening criteria updated from the traditional Wilson and Jungner criteria (W&J), relating to disease, treatment, test and cost. 3. The interest of the child should be central in the assessment of pros and cons. 4. The European NBS body (or the national NBS bodies) should further elaborate the specifications and the operative application of the screening criteria through discussion and agreement with the EU national authorities. 5. HTA to evaluate the evidence on the effectiveness of early detection through neonatal screening and treatment should be achievable in practice. For rare conditions, best level evidence should be used. Methods need to be developed to both optimize health benefit and careful evaluation. 6. Universal screening is generally preferable to ethnical targeted screening. If there are sound reasons (eg, health gain) for targeted screening, it is important to avoid stigmatization. 7. The health system should ensure treatment to all confirmed cases diagnosed by screening. In case of suboptimal availability of treatment, it should plan to make treatment available for all confirmed cases (based on common values and principles in EU Health Systems (universality and access to good quality care)). Criteria on how a screening program should be performed 1. Before the start of an NBS program, all health-care professionals involved must be offered adequate training and sufficient participation must be achieved. 2. The provision of information needs to be organized at program management level by public health authorities and is the responsibility of the NBS program management. This should be developed in collaboration with the relevant users. 3. The information contents and communication guidelines should be defined at program management level; it may take advantage from sharing existing examples and experiences. 4. Sufficient general information on NBS should be given to prospective parents, starting during pregnancy. This could also come up in preconceptional care. Detailed information should be available upon request. On a program level, the responsibility for this pretest information needs to be clarified: public health authorities could mandate obstetric-care providers. 5. Evidence-based patient information on NBS in appropriate language should be made available on websites of the institutions responsible for the screening.
Informed consent
1. NBS must be offered to all infants in the EU. 2. It should be offered as a service governed by appropriate legal provisions, which also ensures compliance with quality requirements of other legislation (such as patient's rights, personal data protection, biobanks, research approval by ethics committee, genetic testing and genetic counseling). The health-care system should cover the costs. 3. The importance of NBS in the best interest of their child should be clarified to parents. Participation should be voluntary. 4. A specific consent should be sought for activities not strictly related to the benefit of the newborn, such as the use for research purposes. 5. The informed consent protocols should be defined at jurisdictional level, in consultation with the appropriate stakeholders; it may take advantage from sharing existing examples and experiences.
Blood spot sampling
1. Blood spot sampling between 48 and 72 h is preferable for most disorders in NBS programs. 2. Uptake needs to be monitored, an uptake of 100% is pursued. If informed consent is taken seriously, this value may not be reached. 3. Systems should be in place to maximize uptake and ensure that babies are not missed 4. Systems should be in place to deal with the families moving into the area and crossing national boundaries to ensure that appropriate screening has been carried out or is offered.
Laboratory procedures
1. The target values and benchmarks ensuring the quality and efficacy of laboratory procedures should be defined at program management level; 2. The development of laboratory procedures should take advantage from sharing existing examples and experiences. 3. Defined screening protocols should be published by each member state and reviewed every 1-5 years or on demand in case of recognized developments. 4. Test turnaround time within the laboratory should be kept short:
for example, a maximum of 48 h is recommended.
Blood spot storage
1. Blood spots need to be stored for quality control in the NBS screening laboratory for at least 5 years. 2. Blood spot storage should ensure appropriate protection of sensitive personal information and of biological samples (eg, compliance with the relevant regulations). 3. Informed consent should be asked, at least for activities not strictly related to the benefit of the newborn, such as storage for quality control and research. For use of the blood spot after 18 years, the child should have the possibility to consent or dissent. 4. Use of blood spots for research purposes is subject to national specific ethical regulations (eg, definition of research objectives and timing, informed consent and approval by the ethical committee). The potential interest for research and the possible misuse of residual NBS specimens have increased the need for regulation of specimen storage and access policies at the European level for both ethical and legal reasons. At the European level, major differences in regulations should be avoided in view of trans-border health care and international research. 
Communication of unintended findings
1. Parents should be given the possibility to be informed of any unintended finding that could be relevant, to the extent this is consistent with laws, individual data protection rights and the right to privacy. 2. Different positions have been taken in the debate on unintended findings. Discussion is needed in countries to develop policy and legislation, if appropriate. This should be published. 3. As far as unintended but relevant information for the health of the child or mother is concerned, parents should be given the possibility to be informed. For the return of information on carrier status, a separate decision, consistent with other relevant national health regulations, is needed in each country. This is because carrier information is mainly important for reproductive choice of the parents and not directly for the health of the screened newborn. The content of the information and guidelines for its communication to parents should be defined at program management level; it may take advantage from sharing existing examples and experiences.
Quality assurance of laboratory results 
Epidemiological evaluation
1. Collaborative international projects are needed to assess the longterm follow-up of the patients with rare conditions identified in NBS programs. Both evaluation of programs (expert opinion no. 65), and the success of screening and treatment for patients and families are needed. The EU should take a pro-active approach to organize long-term follow-up.
Features of disorders, which might be considered in the gradual expansion of NBS in EU
1. Training on all aspects of improving NBS programs should be facilitated at EU level. 2. EU countries should consider the assessment of the first group of disorders (Chapter 5 of the Expert Opinion document) (http:// www.iss.it/cnmr/prog/cont.php?id=1621&lang=1&tipo=64) on the basis of local/national conditions in case that they intend to expand their NBS. This process and conclusions should be published. 3. The EU NBS body, charged with the assessment of the evidence and possibilities for neonatal screening, 8 might consider initiating its activity with reviewing the evidence for disorders to be screened. For the first group of disorders, several countries have assessed the evidence already. Especially the conditions in the second group (Chapter 5 of the Expert Opinion document) (http://www.iss.it/cnmr/prog/cont.php?id=1621&lang=1&tipo=64), where limited evidence is available or different conclusions were reached need to be prioritized. 4. There is an opportunity to use the moment of blood spot screening for other screening programs concerning, for example, hearing loss, hips, eyes and heart.
